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The host cellular immune response to
cytomegalovirus targets the endothelium
and is associated with increased arterial
stiffness in ANCA-associated vasculitis
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Abstract
Background: Cardiovascular disease is a leading cause of death in ANCA-associated vasculitis (AAV). An expansion
of CD4+CD28null T cells is seen mainly in cytomegalovirus (CMV)-seropositive individuals and has been linked to
increased cardiovascular disease risk in other conditions. The aims of this study were to phenotype CD4+CD28null T
cells in AAV with respect to their pro-inflammatory capacity and ability to target and damage the endothelium and
to investigate their relationship to arterial stiffness, a marker of cardiovascular mortality.
Methods: CD4+CD28null T cells were phenotyped in 53 CMV-seropositive AAV patients in stable remission and 30
age-matched CMV-seropositive healthy volunteers by flow cytometry following stimulation with CMV lysate. The
expression of endothelial homing markers and cytotoxic molecules was evaluated in unstimulated CD4+CD28null T
cells. Arterial stiffness was measured by carotid-to-femoral pulse wave velocity (PWV) in patients with AAV.
Results: CD4+CD28null T cells were CMV-specific and expressed a T helper 1 (Th1) phenotype with high levels of
interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) secretion. They also co-expressed the endothelial
homing markers CX3CR1, CD49d and CD11b and cytotoxic molecules perforin and granzyme B. CD4+CD28null T cells
were phenotypically similar in patients with AAV and healthy volunteers but their proportion was almost twice as high
in patients with AAV (11.3% [3.7–19.7] versus 6.7 [2.4–8.8]; P = 0.022). The size of the CD4+CD28null T-cell subset was
independently linked to increased PWV in AAV (0.66 m/s increase per 10% increase in CD4+CD28null cells, 95%
confidence interval 0.13–1.19; P = 0.016).
Conclusion: The host cellular immune response to CMV leads to the expansion of cytotoxic CD4+CD28null T
cells that express endothelial homing markers and are independently linked to increased arterial stiffness, a
marker of cardiovascular mortality. Suppression of CMV in AAV may be of therapeutic value in reducing the
risk of cardiovascular disease.
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Background
Inflammation is a key factor in the pathophysiology of ath-
erosclerosis [1, 2]. The relationship between inflammation
and cardiovascular disease (CVD) is evident in patients
with rheumatic disorders such as rheumatoid arthritis,
systemic lupus erythematosus and ANCA-associated vas-
culitis (AAV), in which CVD is a leading cause of death
[3–5]. Traditional risk factors do not fully explain the in-
creased incidence of CVD seen in these conditions [6],
and it is thought that inflammation and immunopathology
may accelerate atherosclerosis [7].
CD4 T cells that do not express the co-stimulatory mol-
ecule CD28 (CD4+CD28null) have been implicated in vascu-
lar injury [8]. CD4+CD28null T cells are pro-inflammatory
and their proportion expands under inflammatory condi-
tions [9–11]. They are found preferentially in unstable ra-
ther than stable atherosclerotic plaques [12], suggesting
direct involvement in plaque disruption, and they have been
shown in in vitro assays to exhibit endothelial cytotoxicity
in the context of acute coronary syndrome [13] and AAV
[14]. Several studies in patients with inflammatory disorders
such as rheumatoid arthritis have demonstrated that
expansion of CD4+CD28null T cells is independently associ-
ated with increased incidence of CVD and cardiovascular
mortality [15–19].
Loss of the co-stimulatory molecule CD28 on CD4 T
cells suggests repeated exposure to a persistent antigen
[20]. We and others have demonstrated that significant
expansion of CD4+CD28null T cells occurs mainly in
cytomegalovirus (CMV)-seropositive individuals, and
negligible or very low proportions of these cells are seen
in the absence of previous CMV infection [11, 21–24].
CMV infection is widely prevalent in the general popula-
tion [25], and CMV itself has been implicated in the
pathogenesis of CVD [26]. CMV infects endothelial and
smooth muscle cells where it is able to persist during
latency [27]. Infection with CMV is associated with
impaired vascular function [28], high blood pressure
[29], increased arterial stiffness [30] and cardiovascu-
lar mortality [26]. Furthermore, a recent meta-analysis
demonstrated that CMV infection is associated with a
22% increased relative risk for CVD in the general
population [31].
The aims of this study were to characterise the pheno-
type of CD4+CD28null T cells in AAV, with respect to
their pro-inflammatory capacity and ability to target and
damage the endothelium, and to determine whether ex-
pansion of this cell subset is associated with arterial stiff-
ness, a marker of cardiovascular mortality.
Methods
Study population
Fifty-three CMV-seropositive patients with AAV in
stable remission were recruited from the vasculitis clinic
at University Hospitals Birmingham NHS Foundation
Trust (Birmingham, UK), and 30 age-matched CMV-
seropositive healthy volunteers (HVs) were enrolled from
the 1000 Elders Cohort (courtesy of Professor Janet
Lord, University of Birmingham, UK) and patient house-
hold contacts. CD4+CD28null T-cell percentage and
phenotype were assessed in all participants. Arterial stiff-
ness was measured in patients with AAV.
Patients were eligible for inclusion if they had a docu-
mented diagnosis of AAV and were in stable remission
for at least 6 months, on maintenance immunosuppres-
sion with a maximum of two agents, and seropositive for
CMV (anti-CMV IgG detected in peripheral blood). Ex-
clusion criteria were estimated glomerular filtration rate
of less than 15 mL/minute per 1.73 m2, B cell–depleting
therapy within 12 months or T cell–depleting therapy
within 6 months, presence of other chronic infection
(HIV, hepatitis B, hepatitis C, or tuberculosis) and treat-
ment with anti-CMV therapies within the previous
month.
Thirty-eight of 53 patients with AAV were participants in
the ‘Cytomegalovirus modulation of the immune system in
ANca-associated VASculitis’ (CANVAS) clinical trial, a
proof-of-concept open-label randomised trial of valaciclovir,
or no additional treatment, in CMV-seropositive AAV pa-
tients in remission [32]. All immune and arterial stiffness
assessments reported here were conducted at baseline prior
to commencement of valaciclovir.
The study was approved by the Research Ethics Com-
mittee of Yorkshire and the Humber (UK). Written in-
formed consent was obtained from all participants.
Blood collection
Up to 50 mL of peripheral blood was obtained and
processed within a maximum of 5 hours following vene-
puncture. Plasma was isolated by centrifugation and
cryopreserved at −80 °C. Peripheral blood mononuclear
cells (PBMCs) were isolated from heparinised blood by
density gradient centrifugation, used immediately in
stimulation experiments with CMV lysate to identify
cytokine-producing T cells, or cryopreserved in liquid
nitrogen.
Cells for flow cytometry experiments were acquired
on a BD LSR II Flow Cytometer and analysed by using
FACS DIVA Software Version 8.0 (BD, Franklin Lakes,
NJ, USA). Monoclonal antibodies used for flow cytome-
try experiments are listed in Table S1 of Additional file
1. Gating strategies are shown in Figure S1 and S2 of
Additional file 1.
Enumeration of peripheral blood CD4+CD28null T cells
Whole blood was stained with anti-CD3, anti-CD4
and anti-CD28 monoclonal antibodies to determine
CD4+CD28null T-cell percentage. Quality control was
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achieved by using a positive control (Cytofix CD4
Normal Range Positive Control; Cytomark, Caltag
Medsystems, Buckingham, UK) with a validated ac-
ceptance range for CD3+CD4+ percentage and a fluor-
escence minus one control to aid CD28 gating. These
were assayed with every analytical run.
Peripheral blood mononuclear cell stimulation
To identify CMV lysate-stimulated cytokine-expressing T
cells, 0.5–1 × 106 PBMCs were re-suspended in supple-
mented medium—(RPMI), 10% foetal calf serum; sterile
filtered and heat inactivated (Sigma-Aldrich, St. Louis,
MO, USA), 1% penicillin/streptomycin (P/S) (Gibco,
Thermo Fisher Scientific, Waltham, MA, USA—overnight
for 16 (±2) hours at 37 °C, 5% CO2, in the presence of
monensin (2 μmol/L) and phycoerythrin-conjugated
anti-CD154 monoclonal antibody as previously described
[33]. Cells were stimulated with CMV lysate (1:100)
prepared from CMV strain AD169-infected human foetal
foreskin fibroblasts. Unstimulated cells served as controls.
Following overnight incubation, cells were stained with
eFluor-506 viability dye (eBioscience, Thermo Fisher
Scientific) for 30 min at 4 °C, washed with
phosphate-buffered saline and flow cytometry buffer, and
co-stained with saturating amounts of anti-CD3, anti-CD4
and anti-CD28 antibodies for 30 min at 4 °C before wash-
ing with flow cytometry buffer. Cells were fixed and per-
meabilised with an intracellular flow cytometry staining
kit (eBioscience) and stained for 30 min at 4 °C with satur-
ating amounts of anti-interferon-gamma (anti-IFN-γ),
anti-tumour necrosis factor-alpha (anti-TNF-α), anti
-interleukin-2 (anti-IL-2), anti-IL-5, anti-IL-10 and
anti-T-bet monoclonal antibodies before washing with
flow cytometry buffer.
Identification of Th1-, Th2- and Th17-skewed subsets
The expression of chemokine receptors on unstimulated
CD4+CD28null T cells from 17 patients with AAV was de-
fined by staining whole blood with anti-CXCR3,
anti-CCR4, anti-CCR6, anti-CD3, anti-CD4 and anti-CD28
monoclonal antibodies. T helper 1 (Th1)-skewed CD4 T
cells were identified as CXCR3+CCR6−, Th2-skewed as
CCR4+CCR6− and Th17-skewed as CCR4+CCR6+ [34].
Identification of endothelial homing receptors and
cytotoxic molecules
In order to phenotype unstimulated CD4+CD28null T
cells with respect to their expression of endothelial hom-
ing receptors and cytotoxic molecules, cryopreserved
PBMCs from 10 patients with AAV were stained with
Fixable Viability dye eFluor-506 as described above;
co-stained with anti-CD3, anti-CD4, anti-CD28,
anti-CX3CR1, anti-CD49d and anti-CD11b antibodies;
and fixed and permeabilised as already described,
followed by intracellular staining with anti-perforin and
anti-granzyme B antibodies.
Measurement of soluble markers of inflammation
Soluble markers of inflammation (IL-2, TNF-α, IFN-γ,
IL-10, IL-17A, IL-6 and highly sensitive C-reactive pro-
tein) were measured in plasma by Luminex array (Procar-
taPlex, eBioscience) in accordance with the instructions of
the manufacturer, read on a Bio-Rad Luminex 200 instru-
ment (Bio-Rad, Hercules, CA, USA) and analysed by using
ProcartaPlex Analyst 1.0 Software (eBioscience).
Determination of anti-CMV IgG titre
Plasma anti-CMV IgG titre was assayed by using an
enzyme-linked immunosorbent assay as previously de-
scribed [30]. CMV seropositivity was defined as an
anti-CMV IgG titre of more than 10 units.
Arterial stiffness measurement
Arterial stiffness was estimated by measuring carotid-
to-femoral pulse wave velocity (PWV) using the
non-invasive, non-operator-dependent Vicorder system
(Skidmore, Bristol, UK) that employs a volume dis-
placement method, as previously described [32].
Briefly, the patient was allowed to rest for 5 min
prior to inflating a 100-mm-wide cuff on the
non-dominant arm to measure peripheral blood
pressure. A 30-mm-wide cuff was then placed on the
neck at the level of the carotid artery and a
100-mm-wide cuff placed around the proximal thigh.
The distance between the mid-clavicular point and
the mid-point of the thigh cuff, the aortic path
length, was measured with the patient supine. With
the patient at a supine 30° head-tilt position, the
cuffs were inflated to 60 mm Hg. The Vicorder in-
strument uses the resultant oscillometric signal to
extract the pulse waveforms and pulse transit time
to calculate carotid-to-femoral PWV. The mean
value of three consistent readings was used for sub-
sequent analysis.
Statistical analysis
Continuous variables were summarised as medians and
quartiles (unless stated otherwise) and categorical data as
counts and percentages. Groups were compared with the
Mann–Whitney test, the Kruskal–Wallis and Dunn’s mul-
tiple comparison test, and the chi-squared or Fisher’s exact
test. Associations were assessed with Spearman’s rank cor-
relation. Univariable and multivariable linear regression
models were constructed for variables associated with
PWV. Analyses were undertaken by using SPSS Statistics
Version 21 (IBM, Armonk, NY, USA) and Prism Version 5
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(GraphPad, La Jolla, CA, USA) and were two-tailed; a P
value of less than 0.05 was considered significant.
Results
Baseline characteristics of study participants are shown
in Table 1.
CD4+CD28null T cells are CMV-specific and display a pro-
inflammatory phenotype
We initially undertook a phenotypic analysis of
CD4+CD28null T cells from 53 CMV-seropositive AAV
patients in stable remission. PBMCs were stimulated in
vitro with CMV lysate, and the proportion of
CMV-specific cells within the CD4+CD28null and
CD4+CD28+ subfractions was determined. A greater
proportion of CMV-specific T cells was observed within
the CD4+CD28null population as determined by expres-
sion of the activation marker CD154 and cytokine ex-
pression: IFN-γ, TNF-α and IL-2 (Fig. 1a). Neither cell
type expressed significant amounts of IL-5 or IL-10.
The percentage of CD4+CD28null T cells was strongly
correlated with the total CMV-specific CD4+ response
(rho = 0.846, P <0.001; Fig. 1b), indicating that the size of
the CD4+CD28null T-cell accumulation is a good measure
of the impact of CMV infection on the CD4 compartment
in this population. CD4+CD28null T-cell percentage also
correlated with the humoral response to CMV, anti-CMV
IgG titre (rho = 0.324, P = 0.018; Fig. 1b).
As well as expressing IFN-γ and TNF-α, the majority
of CD4+CD28null T cells expressed the Th1 lineage tran-
scription factor T-bet (Fig. 1c) and a Th1-skewed che-
mokine receptor profile (CXCR3+CCR6−) (Fig. 1d). In
contrast, the chemokine receptor staining profile that
identifies Th2-skewed (CCR4+CCR6−) and Th17-skewed
(CCR4+CCR6+) cells was not seen on CD4+CD28null T
cells. Indeed, CD4+CD28null T cells comprised the major-
ity of the Th1 compartment (median 51.6%, 30.0–77.3). In
addition, the percentage of CD4+CD28null T cells was
strongly correlated with the overall size of the Th1 com-
partment (Fig. 1c), indicating that the size of the
CD4+CD28null T-cell expansion in CMV-seropositive
AAV patients determines the relative proportion of Th1
cells, a subset known to exert a strong pro-atherosclerotic
effect [35].
There was no difference between AAV patients and
age-matched CMV-seropositive HVs in the induction of
CD154 expression on CD4+CD28null T cells or their
cytokine expression profile following CMV lysate stimu-
lation (Fig. 1e). However, patients with AAV had larger
expansions of CD4+CD28null T cells compared with HVs
(11.3% [3.7–19.7] versus 6.7 [2.4–8.8]; P = 0.022).
CD4+CD28null T cells are endothelial homing cytotoxic T
cells
IFN-γ and TNF-α activate endothelial cells and increase
surface expression of chemokines and adhesion mole-
cules such as IFN-γ–inducible protein-10 (IP-10), frac-
talkine, vascular adhesion molecule-1 (VCAM-1) and
intercellular adhesion molecule-1 (ICAM-1) [36]. Having
identified high levels of expression of the IP-10 receptor
CXCR3 on the surface of CD4+CD28null T cells, we
evaluated the surface expression of the receptors for
fractalkine, VCAM-1 and ICAM-1 (CX3CR1, CD49d
and CD11b) on unstimulated PBMCs from 10 patients
with AAV. Co-expression of all three endothelial homing
receptors was significantly more common on CD4+
Table 1 Participant baseline characteristics
AAV (n = 53) HV (n = 30)
Age, years 69.0 [62.8–75.3] 70.5 [66.8–74.0]*
Gender, male:female 35:18 14:16*
ANCA specificity, PR3:MPO 34:18 –
AAV disease chronicity, years 6.0 [3.2–12.0] –
Renal function eGFR, mL/min per 1.73 m2 53 [21] –
Urine albumin-to-creatinine ratio, mg/mmol 4.4 [1.4–9.9] –
Steroids, n (%) 39 (73.6) –
Mycophenolate mofetil, n (%) 14 (26.4) –
Azathioprine, n (%) 19 (35.8) –
No current immunosuppression, n (%) 4 (7.5) –
Ever smoker, n (%) 26 (49.1) –
Diabetes mellitus, n (%) 11 (20.8) –
On statin treatment, n (%) 29 (54.7)
Data are displayed as median [interquartile range] apart from renal function displayed as mean [standard deviation]. Immunosuppressive treatment refers to
number and percentage of patients on the respective immunosuppressive agent at the time of study entry.
*Comparison between ANCA-associated vasculitis (AAV) and healthy volunteers (HV): age (Mann–Whitney U test, P = 0.557), gender (Fisher’s exact, P = 0.106)
Abbreviations: eGFR estimated glomerular filtration rate, MPO myeloperoxidase, PR3 proteinase 3
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CD28null compared with CD4+CD28+ T cells (51.6%
[42.7–64.4] versus 5.0 [1.7–6.3]; P = 0.006; Fig. 2a). In
addition, the majority of unstimulated CD4+CD28null T
cells contained intracellular stores of both perforin and
granzyme B (74.5%, 63.5–92.7; Fig. 2b), suggesting that
they have the capacity to target and lyze endothelial
cells.
The size of the CD4+CD28null T-cell expansion is
independently associated with increased arterial stiffness
in AAV
To determine whether the size of the CD4+CD28null
T-cell expansion is associated with arterial stiffness, as a
clinical marker of cardiovascular pathology, carotid-
to-femoral PWV was measured in the patients with
AAV. The CD4+CD28null T-cell percentage was found
to be significantly correlated with increased systolic
blood pressure (rho = 0.305, P = 0.026), pulse pres-
sure (rho = 0.428, P = 0.001) and PWV (rho = 0.371,
P = 0.006; Fig. 3).
On univariable analysis, age, percentage of CD4+
CD28null T cells, plasma concentration of TNF-α, and
blood pressure parameters (Table 2) were associated
with increased PWV. In contrast, we did not observe an
association between anti-CMV IgG titre and PWV.
To account for confounding factors, we constructed a
multivariable linear regression model including all vari-
ables that were associated with PWV on univariable
Fig. 1 CD4+CD28null T cells are cytomegalovirus (CMV)-responsive T helper 1 (Th1) pro-inflammatory T cells. a Following stimulation with CMV
lysate, a greater proportion of CD4+CD28null T cells (open circles) expressed the activation marker CD154 and secreted interferon-gamma (IFN-γ),
tumour necrosis factor-alpha (TNF-α) and interleukin-2 (IL-2) compared with CD4+CD28+ T cells (grey squares) (ANCA-associated vasculitis [AAV],
n = 53). b CD4+CD28null T-cell percentage correlated with the size of the total CD4 CMV response and with the anti-CMV IgG antibody titre (AAV,
n = 53). c A greater proportion of CD4+CD28null T cells expressed the Th1 transcription factor T-bet compared with CD4+CD28+ T cells and
CD4+CD28null T-cell percentage correlated with the percentage of CD4 T cells expressing T-bet (AAV, n = 53). d CD4+CD28null T cells exhibited a
Th1 lineage chemokine receptor pattern rather than Th2 or Th17 (AAV, n = 17). e There was no difference in the cytokine expression profile
between AAV (n = 53, open circles) and healthy volunteers (HV) (n = 30, open triangles), but patients with AAV contained larger expansions of
CD4+CD28null T cells. **P < 0.01, ***P < 0.001. All bars are medians. Abbreviation: ns not significant
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analysis with a P value of less than 0.1 (Tables 2 and 3).
This demonstrated that the percentage of CD4+CD28null
T cells associated with increased arterial stiffness inde-
pendently of age, proteinuria, peripheral mean arterial
blood pressure, and plasma concentration of TNF-α.
There was a 0.66 m/s [95% confidence interval 0.13–1.19]
increase in PWV for every 10% increase in CD4+CD28null
T cells (P = 0.016; Table 3). This relationship did not
change when systolic blood pressure or pulse pressure
was substituted for mean arterial blood pressure, and the
Fig. 2 CD4+CD28null T cells are endothelial homing, cytotoxic T cells. Unstimulated CD4 T cells from patients with ANCA-associated vasculitis
(AAV) (n = 10) were stained for expression of endothelial homing receptors CX3CR1, CD49d and CD11b and intracellular cytotoxic molecules
perforin and granzyme B. a Representative staining and summary data for unstimulated CD4 T cells gated on CD4+CD28null (top two flow
cytometry plots) and CD4+CD28+ T cells (bottom two flow cytometry plots). Sequential gating was performed as follows: CD49d and CD11b to
identify CD49d CD11b double-positive cells, followed by CX3CR1 to identify CD49d CD11b CX3CR1 triple-positive cells. b Representative staining
and summary data for unstimulated CD4 T cells gated on CD4+CD28+ and CD4+CD28null T cells showing cells double-positive for perforin and
granzyme B
Fig. 3 CD4+CD28null T-cell expansion correlates with increased arterial stiffness and blood pressure parameters. CD4+CD28null T-cell percentage
correlated with increased systolic blood pressure (a), pulse pressure (b), a surrogate marker of arterial stiffness, and carotid-to-femoral pulse wave
velocity (c) (n = 53)
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size of the CD4+CD28null T-cell expansion remained inde-
pendently associated with increased PWV.
Discussion
Our findings demonstrate that the host cellular immune
response to CMV is associated with the expansion of a
subset of pro-inflammatory, endothelial homing, cyto-
toxic CD4+CD28null T cells in patients with AAV. Fur-
thermore, the size of this expansion is independently
linked to increased arterial stiffness, a marker of cardio-
vascular mortality [37]. This is significant in AAV as
cardiovascular disease is a leading cause of death in this
patient group.
Our data provide further insight into the properties of
CD4+CD28null T cells and their capacity to cause
vascular damage of relevance to AAV. We identified
CD4+CD28null T cells in AAV to be Th1-skewed
pro-inflammatory T cells that produce IFN-γ and TNF-α
in response to stimulation with CMV lysate. These find-
ings are in keeping with previous reports in HVs [38] as
well as in AAV where CD4+CD28null T cells have been
shown to be a major source of IFN-γ and TNF-α [39].
Table 2 Variables associated with pulse wave velocity on univariable analysis
Variable Univariable analysis
R2 Regression coefficient [95% CI] P value
Age, years 0.183 0.131 [0.053, 0.208] 0.001
Gender 0.004 0.393 [− 1.313, 2.100] 0.645
eGFR, mL/min per 1.73 m2 0.026 − 0.023 [− 0.062, 0.017] 0.252
Urinary albumin-to-creatinine ratio, mg/mmol 0.056 0.019 [−0.003, 0.041] 0.088
Ever smoker 0.017 −0.759 [−2.364, 0.847] 0.347
Presence of diabetes 0.002 0.291 [−1.704, 2.286] 0.771
On statin treatment 0.044 1.208 [−0.383, 2.799] 0.134
Pulse pressure, mm Hg 0.163 0.084 [0.030, 0.137] 0.003
Mean arterial pressure, mm Hg 0.102 0.088 [0.015, 0.161] 0.020
Systolic blood pressure, mm Hg 0.191 0.079 [0.033, 0.124] 0.001
Diastolic blood pressure, mm Hg 0.027 0.056 [−0.039, 0.150] 0.243
CD4+CD28null T-cell proportion (%), per 10% increase 0.182 0.912 [0.368, 1.455] 0.001
C-reactive protein, mg/mL 0.008 −0.234 [− 0.958, 0.490] 0.520
IL-2, pg/mL 0.066 0.007 [0.000, 0.015] 0.065
IFN-γ, pg/mL 0.036 −0.004 [− 0.010, 0.002] 0.179
IL-10, pg/mL 0.025 0.089 [−0.068, 0.245] 0.260
IL-6, pg/mL 0.004 0.002 [−0.007, 0.011] 0.649
TNF-α, pg/mL 0.083 0.015 [0.001, 0.029] 0.039
IL-17, pg/mL 0.015 −0.003 [−0.011, 0.004] 0.389
All variables with a P value of less than 0.1 on univariable analysis were included in the multivariable model shown in Table 3
Abbreviations: CI confidence interval, eGFR estimated glomerular filtration rate, IL interleukin, TNF-α tumour necrosis factor-alpha
Table 3 Multivariable linear regression model for pulse wave velocity (meters per second)
Variable Univariable analysis Multivariable analysis
Regression coefficient [95% CI] P value Regression coefficient [95% CI] P value
CD4+CD28null T-cell percentage, per 10% increase 0.912 [0.368, 1.455] 0.001 0.663 [0.132, 1.194] 0.016
Age, years 0.131 [0.053, 0.208] 0.001 0.080 [0.006, 0.155] 0.035
Proteinuria (urinary ACR), mg/mmol 0.019 [−0.003, 0.041] 0.088 0.013 [−0.007, 0.033] 0.196
Mean arterial pressure, mm Hg 0.088 [0.015, 0.161] 0.020 0.053 [−0.016, 0.122] 0.128
TNF-α, pg/mL 0.015 [0.001, 0.029] 0.039 0.010 [−0.002, 0.022] 0.086
Variables with P value of less than 0.1 on univariable analysis (Table 2) were included in the model. In order to avoid collinearity, only one blood pressure
parameter and either plasma concentration of tumour necrosis factor-alpha (TNF-α) or interleukin-2 (IL-2) were added at each iteration of the model. This table
shows the final model with mean arterial pressure (MAP) and TNF-α. The size of the CD4+CD28null T-cell expansion remained independently associated with pulse
wave velocity with negligible impact on the model characteristics when pulse pressure or systolic blood pressure was substituted for MAP and when plasma
concentration of IL-2 was substituted for TNF-α
R value: 0.635, R2: 0.404
Abbreviations: ACR albumin-to-creatinine ratio, CI confidence interval
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Th1 T cells are recognised as important players in the
atherosclerotic process with Th1-driven responses exert-
ing detrimental effects [40]. Mice deficient in T-bet, the
master regulator of the Th1 transcriptional response, are
relatively protected from the development of athero-
sclerotic lesions [35], and both T-bet and IFN-γ are es-
sential in the generation of angiotensin II–mediated
vascular dysfunction [41]. We observed that the CD4
Th1 compartment in AAV CMV-seropositive patients
was made up mostly of CD4+CD28null T cells and that
up to 94% of Th1 cells were CD4+CD28null. Taken to-
gether, our findings indicate that CMV exerts a powerful
influence on the shape and magnitude of the Th1
repertoire.
IFN-γ and TNF-α cytokines mediate inflammation in
blood vessel walls through disruption of endothelial
junctions and induction of chemokine and adhesion
molecule expression on vascular endothelium. This
promotes the recruitment and adherence of lympho-
cytes and monocytes on the inflamed endothelium
and facilitates leukocyte transmigration [36]. In our
phenotypic analysis, CD4+CD28null T cells were found
to express the chemokine receptors CX3CR1, CD49d,
CD11b and CXCR3 that are able to bind their re-
spective adhesion molecule ligands fractalkine,
VCAM-1, ICAM-1 and IP-10 on activated endothelial
cells [42, 43]. They also co-expressed the cytolytic
granules granzyme B and perforin, as previously
found by others [44], suggesting that they act as cyto-
toxic effector cells. The endothelium is an important
site for CMV infection [27] and as such endothelial
targeting by CMV-specific T cells would be expected
to have the capacity to suppress viral reactivation but
might also contribute to vascular damage.
Consistent with these observations, our findings re-
vealed that the size of the CD4+CD28null T-cell expansion
in patients with AAV was independently associated with
increased arterial stiffness. This is contrary to a recent re-
port in patients with AAV where the size of the
CD4+CD28null T-cell expansion was found not to be re-
lated to arterial stiffness [45]. However, the AAV cohort
within that study included a substantial proportion of
CMV-seronegative patients and only 24 patients were
CMV-seropositive. Given that significant expansion of
CD4+CD28null T cells is seen mainly in CMV-seropositive
individuals, this may explain the discrepancy between our
findings and those of Slot et al. [45]. Furthermore, our
data are in agreement with several published studies
reporting associations in other patient groups such as
rheumatoid arthritis [15] and chronic kidney disease [18],
between CD4+CD28null T cells and markers of atheroscler-
otic damage.
Previous work by our group has shown that
CMV-seropositive patients with chronic kidney disease
have stiffer arteries compared with CMV-seronegative
chronic kidney disease patients [30]. In the present study,
we observed that expansion of CD4+CD28null T cells in
CMV-seropositive AAV patients is associated with in-
creased arterial stiffness in that carotid-to-femoral PWV
increases by 0.66 m/s for every 10% increase in the size of
the CD4+CD28null T-cell subset. Such an effect size on
PWV is greater than the impact of smoking on arterial
stiffness [46] and roughly equivalent to 10 years’ worth of
ageing [47]. In contrast, we found no correlation between
the humoral response to CMV, measured by the
anti-CMV IgG titre, and arterial stiffness. Based on our
data, we propose that the host cellular immune response
to CMV is directly involved in the development of cardio-
vascular pathology and that this is driven by the expansion
of the pro-inflammatory endothelial homing CD4+
CD28null T-cell subset. However, it should be noted that
our study was cross-sectional in nature and therefore can-
not definitively confirm a longitudinal increase in arterial
stiffness driven by CD4+CD28null T cells.
It is likely that expansion of CD4+CD28null T cells it-
self is driven by asymptomatic subclinical reactivation of
CMV. Viral reactivation is more likely to occur in an in-
flammatory milieu, and TNF-α has recently been shown
to reverse the transcriptional silencing that maintains
CMV latency, leading to lytic reactivation [48]. We re-
cently observed that subclinical CMV reactivation oc-
curs in over a quarter of patients with AAV in remission
within a 12-month period [49], indicating that CMV re-
activation is a frequent event in this patient group. This
could explain our finding that CD4+CD28null T-cell ex-
pansions are almost twice as large in AAV patients com-
pared with age-matched HVs. Subclinical CMV
reactivation is likely to be even higher during the acute
phase of AAV, when patients are exposed to high levels
of systemic inflammation and intensive immunosuppres-
sive treatment. As viral reactivation is expected to act as
a potent stimulus for boosting the CMV-specific cellular
immune response, anti-viral therapy could act to sup-
press CMV-specific immune responses and potentially
reduce cardiovascular damage. Anti-viral therapy in this
context would suppress all herpes viruses. This could be
advantageous as recent evidence suggests that concomi-
tant CMV and Epstein–Barr virus infection may be asso-
ciated with increased expansion of CD4+CD28null T cells
in AAV [50].
Conclusions
In summary, the results presented here support a mech-
anism for vascular damage secondary to expansion of
pro-inflammatory CMV-specific T cells that target the
endothelium and are independently linked to arterial
stiffness. Our data suggest that suppression of CMV
may hold therapeutic potential for patients with AAV,
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lending support to the design of further studies aiming
to determine whether CMV suppression might reduce
expansion of CD4+CD28null T cells, ameliorating surro-
gate markers of atherosclerotic damage, and ultimately
reducing risk of cardiovascular disease, the leading cause
of death in this patient group.
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